Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
US Market
Holding GPCR?
Track your performance easily

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Financial Statements

559 Followers

Structure Therapeutics, Inc. Sponsored ADR Financial Overview

Structure Therapeutics, Inc. Sponsored ADR's market cap is currently ―. The company's EPS TTM is $-2.238; its P/E ratio is -16.98; Structure Therapeutics, Inc. Sponsored ADR is scheduled to report earnings on November 12, 2024, and the estimated EPS forecast is $-0.19. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -25.98M$ -32.02M$ -30.99M$ -26.14M$ -23.16M
EBITDA$ -25.75M$ -31.79M$ -30.92M$ -26.07M$ -23.09M
Net Income Common Stockholders$ -26.03M$ -26.04M$ -24.50M$ -23.86M$ -23.28M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 927.12M$ 436.45M$ 467.32M$ 205.42M$ 224.59M
Total Assets$ 947.03M$ 457.23M$ 482.02M$ 216.37M$ 229.43M
Total Debt$ 4.67M$ 5.13M$ 5.45M$ 3.85M$ 73.00K
Net Debt$ -922.45M$ -431.32M$ -461.87M$ -201.57M$ -224.51M
Total Liabilities$ 26.00M$ 27.41M$ 29.05M$ 23.41M$ 15.01M
Stockholders Equity$ 921.07M$ 429.82M$ 452.97M$ 192.96M$ 214.41M
Cash Flow-
Free Cash Flow$ -26.82M$ -34.24M$ -22.89M$ -21.38M$ -17.09M
Operating Cash Flow$ -26.39M$ -34.08M$ -21.73M$ -20.56M$ -16.89M
Investing Cash Flow$ -204.51M$ 1.42M$ -180.74M$ 30.13M$ -68.71M
Financing Cash Flow$ 514.70M$ 702.00K$ 281.63M$ 473.00K$ -297.00K
Currency in USD

Structure Therapeutics, Inc. Sponsored ADR Earnings and Revenue History

Structure Therapeutics, Inc. Sponsored ADR Debt to Assets

Structure Therapeutics, Inc. Sponsored ADR Cash Flow

Structure Therapeutics, Inc. Sponsored ADR Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis